These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 34978854)

  • 1. In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 d.
    Lau D; Saxinger L
    Ann Intern Med; 2022 Jan; 175(1):JC5. PubMed ID: 34978854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
    O'Brien MP; Forleo-Neto E; Musser BJ; Isa F; Chan KC; Sarkar N; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Hou P; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
    N Engl J Med; 2021 Sep; 385(13):1184-1195. PubMed ID: 34347950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme.
    Ducloux D; Courivaud C
    Kidney Int; 2022 Mar; 101(3):645-646. PubMed ID: 34995651
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes.
    Hayek S; Ben-Shlomo Y; Dagan N; Reis BY; Barda N; Kepten E; Roitman A; Shapira S; Yaron S; Balicer RD; Netzer D; Peretz A
    Nat Commun; 2022 Aug; 13(1):4480. PubMed ID: 35918340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders.
    Stein D; Oviedo-Orta E; Kampman WA; McGinniss J; Betts G; McDermott M; Holly B; Lancaster JM; Braunstein N; Yancopoulos GD; Weinreich DM
    Clin Infect Dis; 2022 Aug; 75(1):e509-e515. PubMed ID: 34971385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough omicron COVID-19 infections in patients receiving the REGEN-Cov antibody combination.
    Flahault A; Touchard J; Péré H; Ulrich L; Sabatier B; Veyer D; Lebeaux D; Thervet E
    Kidney Int; 2022 Apr; 101(4):824-825. PubMed ID: 35157894
    [No Abstract]   [Full Text] [Related]  

  • 7. Timing of REGEN-COV administration and progression to severe COVID-19.
    Kadowaki T; Imajou S; Matsumoto N; Takao S; Yorifuji T
    J Infect Chemother; 2022 Nov; 28(11):1459-1463. PubMed ID: 35817250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort study.
    Kumar V J; Banu S; Sasikala M; Parsa KVL; Sowpati DT; Yadav R; Tallapaka KB; Siva AB; Vishnubhotla R; Rao GV; Reddy DN
    J Intern Med; 2022 Mar; 291(3):380-383. PubMed ID: 34719811
    [No Abstract]   [Full Text] [Related]  

  • 9. Retrospective Case-Control Study of REGEN-COV (Casirivimab and Imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan® Database.
    Takemoto K
    Oncology; 2024; 102(3):195-205. PubMed ID: 37666220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.
    O'Brien MP; Forleo-Neto E; Musser BJ; Isa F; Chan KC; Sarkar N; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Hou P; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM
    medRxiv; 2021 Jun; ():. PubMed ID: 34159344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19.
    Med Lett Drugs Ther; 2021 Oct; 63(1635):163-164. PubMed ID: 35050242
    [No Abstract]   [Full Text] [Related]  

  • 12. In critically ill patients with COVID-19, therapeutic anticoagulation did not increase organ support-free days.
    Donato AA
    Ann Intern Med; 2021 Dec; 174(12):JC135. PubMed ID: 34871054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.
    Aisenberg GM
    Ann Intern Med; 2022 Aug; 175(8):JC92. PubMed ID: 35914259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eua for Regen-Cov Now Includes COVID-19 Postexposure Prophylaxis.
    Aschenbrenner DS
    Am J Nurs; 2021 Nov; 121(11):22. PubMed ID: 34673689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
    Merison T; Goldman A; Bomze D
    N Engl J Med; 2021 Nov; 385(20):e70. PubMed ID: 34614318
    [No Abstract]   [Full Text] [Related]  

  • 16. Tofacitinib reduced death or respiratory failure at 28 d in patients hospitalized with COVID-19 pneumonia.
    Tong SYC; Petersiel N
    Ann Intern Med; 2021 Oct; 174(10):JC111. PubMed ID: 34606317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. Reply.
    O'Brien MP; Hou P; Weinreich DM
    N Engl J Med; 2021 Nov; 385(20):e70. PubMed ID: 34614319
    [No Abstract]   [Full Text] [Related]  

  • 18. The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d.
    Sacks HS
    Ann Intern Med; 2021 Jul; 174(7):JC75. PubMed ID: 34224270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.
    Sacks HS
    Ann Intern Med; 2021 Nov; 174(11):JC124. PubMed ID: 34724399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of monoclonal antibody therapy for COVID-19 patients using a risk scoring system.
    Mutoh Y; Umemura T; Ota A; Okuda K; Moriya R; Tago M; Soejima K; Noguchi Y; Bando T; Ota S; Sato T; Hirota S; Hagimoto S; Takei R; Sasano H; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Ichihara T; Kondoh Y
    J Infect Chemother; 2022 Feb; 28(2):352-355. PubMed ID: 34863647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.